Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) CFO Sells $352,534.44 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $58.58, for a total value of $352,534.44. Following the transaction, the chief financial officer directly owned 40,036 shares of the company’s stock, valued at approximately $2,345,308.88. This represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Benjamin Hohl also recently made the following trade(s):

• On Friday, July 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The shares were sold at an average price of $52.64, for a total value of $316,787.52.
• On Wednesday, June 17th, Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock. The stock was sold at an average price of $43.80, for a total transaction of $263,588.40.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $59.82 on Friday. The firm’s fifty day moving average price is $52.99 and its 200 day moving average price is $41.97. Enliven Therapeutics, Inc. has a 1-year low of $14.78 and a 1-year high of $62.32. The firm has a market cap of $4.38 billion, a price-to-earnings ratio of -35.82 and a beta of 0.27.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). As a group, analysts expect that Enliven Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after buying an additional 594 shares in the last quarter. Invesco Ltd. grew its stake in shares of Enliven Therapeutics by 4.3% during the second quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock valued at $440,000 after acquiring an additional 913 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Enliven Therapeutics by 33.3% during the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after acquiring an additional 930 shares in the last quarter. KBC Group NV purchased a new stake in shares of Enliven Therapeutics during the first quarter worth about $38,000. Finally, Swiss National Bank lifted its stake in shares of Enliven Therapeutics by 1.7% in the fourth quarter. Swiss National Bank now owns 64,273 shares of the company’s stock worth $990,000 after acquiring an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ELVN shares. William Blair initiated coverage on Enliven Therapeutics in a research note on Tuesday. They issued an “outperform” rating on the stock. Barclays assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday. They set an “overweight” rating and a $78.00 price objective for the company. The Goldman Sachs Group increased their price objective on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Stifel Nicolaus raised their target price on shares of Enliven Therapeutics from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, HC Wainwright boosted their target price on shares of Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Thursday, July 9th. Eight analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $75.00.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.